The estimated Net Worth of James E Deerfield Mgmt L.P.... is at least $11.5 Million dollars as of 27 June 2019. Mr P owns over 699,475 units of Aclaris Therapeutics Inc stock worth over $3,727,815 and over the last 6 years he sold ACRS stock worth over $7,742,486.
Mr has made over 5 trades of the Aclaris Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 699,475 units of ACRS stock worth $1,881,588 on 27 June 2019.
The largest trade he's ever made was buying 843,352 units of Aclaris Therapeutics Inc stock on 29 May 2018 worth over $15,998,387. On average, Mr trades about 290,389 units every 44 days since 2018. As of 27 June 2019 he still owns at least 3,159,165 units of Aclaris Therapeutics Inc stock.
You can see the complete history of Mr P stock trades at the bottom of the page.
James Loerop is the Chief Bus. Officer at Aclaris Therapeutics Inc.
Mr Loerop is 56, he's been the Chief Bus. Officer of Aclaris Therapeutics Inc since . There are 3 older and 10 younger executives at Aclaris Therapeutics Inc. The oldest executive at Aclaris Therapeutics Inc is Maxine Gowen, 62, who is the Independent Director.
James's mailing address filed with the SEC is 780 3rd Ave, New York, NY 10017, USA.
Over the last 9 years, insiders at Aclaris Therapeutics Inc have traded over $101,608,525 worth of Aclaris Therapeutics Inc stock and bought 10,163,038 units worth $66,383,599 . The most active insiders traders include Braden Michael Leonard, Capital Management, Llc Kol..., and Llc Fmr. On average, Aclaris Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $111,818. The most recent stock trade was executed by Kevin Balthaser on 1 September 2024, trading 1,000 units of ACRS stock currently worth $1,180.
aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.
Aclaris Therapeutics Inc executives and other stock owners filed with the SEC include: